Willow Biosciences Inc. announced that it has advanced its work on its proprietary yeast strain for production of Tetrahydrocannabinol, and plans to commercially launch in the Canadian market. The Company's Canadian based research and development group has developed a proprietary yeast strain and process for the production of THC and is working toward a pilot scale run later this year. While there is already a well-established market for THC in Canada, the company believes there is significant demand from consumer product manufacturers looking for a consistent, high-purity, odorless, flavourless THC ingredient like Willow's for the 2.0 market, which consists of vapes, edibles, beverages, concentrates and topicals. The THC market for 2.0 products is already a multi-billion-dollar, multi-ton addressable market for Willow to sell into. The company has identified a development partner for product isolation, purification and scale up to pilot and is in talks with several manufacturing companies in Canada to serve the adult-use market. The company will launch its THC into the Canadian adult-use market first due to its highly-regulated, legal and developed status. The company is carefully watching the developments in the United States surrounding potential legalization and will be ready to react to any positive regulatory changes should they arise.